Clinical TrialJul 14, 2026, 04:19 PM
Mobia Medical: Vivistim Therapy Shows Sustained 2-Year Stroke Recovery
AI Summary
Mobia Medical announced the publication of two-year follow-up data from its VNS-REHAB study in Neurology, demonstrating sustained and clinically meaningful improvements in upper-limb motor impairment and function for stroke survivors. The data shows that benefits from Vivistim Paired VNS Therapy, including improved daily living activities and quality of life, were maintained for at least two years, with some participants showing continued recovery into the third year. These findings represent comprehensive longitudinal evidence for chronic ischemic stroke recovery interventions.
Key Highlights
- 76% of participants showed clinically meaningful response on FMA-UE and/or WMFT.
- Average improvement of +7.5 points on FMA-UE, exceeding MCID of ≥6 points.
- Average improvement of +0.63 on WMFT, exceeding MCID of ≥0.4 points.
- Statistically significant and clinically meaningful improvements sustained for at least two years.
- Positive three-year outcomes observed in 16 participants, indicating durable benefits.
- No long-term serious adverse events related to therapy or stimulation reported through two years.
Price Impact
More from MOBI